Phase 3 N=32 Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 29; 5 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=188 A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Percent of Patients With a Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology 30 (ACR30) Flare in Part II of the Study (Weeks 16-40) — 48.1; 25.6…
Phase 4 N=85 Trial of Early Aggressive Drug Therapy in Juvenile Idiopathic Arthritis
Juvenile Chronic Polyarthritis · Juvenile Idiopathic Arthritis · Juvenile Rheumatoid Arthritis
Primary: Proportion of Participants Who Attain Inactive Disease by 6 Months — 10; 17 participants
Phase 3 N=133 Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)
Arthritis, Juvenile Idiopathic
Primary: Number of Subjects in the Non-MTX Stratum With Disease Flare During the Double-Blind Phase — 13; 20 Participants — p=0.031
Phase 3 N=193 Pediatric Arthritis Study of Certolizumab Pegol
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Primary: Certolizumab Pegol (CZP) Plasma Concentration Level at Week 16 — 1.6166; 9.2277; 13.8928; 22.9060 ug/ml
Phase 3 N=783 Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
Juvenile Idiopathic Arthritis
Primary: Composite of All Primary Endpoints — 13; 14; 41; 245 Participants — p=0.7357
Phase 3 N=112 A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis
Primary: Part I: Percentage of Participants With ≥30% Improvement in Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Core Set and Absence of Fever…
Phase 3 N=130 A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy
Arthritis, Juvenile
Primary: Serum Trough Concentration (C-trough) of Golimumab — 0.50 micrograms per milliliter (mcg/mL)
Phase 3 N=127 Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
Juvenile Idiopahtic Arthritis
Primary: Number of Participants With Malignancy: All Periods of Parent and Extension Study — 1 Participants
Phase 3 N=20 Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan
Juvenile Idiopathic Arthritis
Primary: Percentage of Participants Experiencing a American College of Rheumatology (ACR) Pediatric 30 Response at Week 16 — 90.0 percentage of participants
Phase 3 N=7 A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Adverse Events of Special Interest and Study-Drug Related Adverse Events — 6; 0; 1; 1 participants
Phase 3 N=69 Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)
Juvenile Rheumatoid Arthritis
Primary: Percentage of Participants With Disease Flare in Part 2 — 81; 28 percentage of participants — p=0.0030
Phase 3 N=190 BMS-188667 in Children and Adolescents With Juvenile Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis
Primary: Time to Occurrence of Juvenile Rheumatoid Arthritis/Juvenile Idiopathic Arthritis (JRA/JIA) Disease Flare During Double-Blind Phase (Period B) — NA; 6 months — p=0.0002
Phase 3 N=225 Efficacy Study Of Tofacitinib In Pediatric JIA Population
Juvenile Idiopathic Arthritis
Primary: Double Blind Phase: Percentage of Participants With Disease Flare According to Pediatric Rheumatology Collaborative Study Group/Pediatric Rheumatology International…
Phase 2 N=71 Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults
Juvenile Idiopathic Arthritis
Primary: Time to Response to Treatment, as Determined by a Modified JIA ACR30 Requiring no Fever, Coupled With a Requirement for Corticosteroid Taper in Participants Who Are…
Phase 2 N=6 Human Anti-Tac (Daclizumab) to Treat Juvenile Idiopathic Arthritis (JIA)-Associated Uveitis
Anterior Uveitis · Arthritis, Juvenile Idiopathic · Iritis
Primary: Number of Participants With a Two-step Reduction in Inflammation — 5 participants
Phase 3 N=25 Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis
Primary: Number of Subjects Achieving Pediatric American College of Rheumatology 30% (PedACR30) Response at Week 16 — 23 Participants
Phase 3 N=219 Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
Active Polyarticular Juvenile Idiopathic Arthritis
Primary: Abatacept Trough Concentration (Cmin) in Participants Ages 6 to 17 — 39.7 µg/mL
N/A N=113 Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Treatment-Related Adverse Events of Etanercept — 22 participants
Phase 3 N=7 A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Any Adverse Events and Any Serious Adverse Events — 7; 0 participants
Phase 4 N=12 Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs) — 12; 7; 5; 0 participants
Phase 2 N=102 An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)
Juvenile Idiopathic Arthritis
Primary: Maximum Serum Concentration (Cmax) of Sarilumab at Week 12 — 7.57; 13.7; 22.0; 33.6 milligram per liter (mg/L)
Phase 4 N=10 Abatacept in Juvenile Dermatomyositis
Dermatomyositis
Primary: Number of Patients Meeting the Definition of Improvement (DOI) at Week 24: at Least 3 of 6 Core Set Measures (CSM) Improved by ≥ 20% With no More Than 2 CSM Worsening by…
Phase 1 N=26 Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis
Primary: Apparent Oral Clearance (CL/F) — 28.09; 25.48; 20.53 liter per hour
Phase 3 N=86 Secukinumab Safety and Efficacy in Juvenile Psoriatic Arthritis (JPsA) and Enthesitis-related Arthritis (ERA)
Juvenile Psoriatic Arthritis · Enthesitis-related Arthritis
Primary: Number of Participants Experiencing a Flare During Treatment Period 2 — 10; 21 Participants — p=<0.001
Phase 2 N=17 Open Label, Multicentre Trial to Assess Safety and Efficacy of ITF2357 in Active Systemic Juvenile Idiopathic Arthritis
Active Systemic · Onset Juvenile Idiopathic Arthritis
Primary: Number of Patients Completing Week 12 of Treatment — 9; 10; 0; 7 Participants
Phase 3 N=55 An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
Juvenile Psoriatic Arthritis · Enthesitis Related Arthritis
Primary: Percentage of Participants With Juvenile Idiopathic Arthritis American College of Rheumatology (JIA ACR) 30 Response — 100; 100; 100; 100 Percentage of Participants
Phase 3 N=302 Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Number of Participants With Laboratory Test Abnormalities — 294 Participants
Phase 3 N=220 A Study of Baricitinib in Participants From 2 Years to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis
Primary: Time to Disease Flare — NA; 27.14 Weeks — p=<0.001
Phase 3 N=177 Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
Systemic Juvenile Idiopathic Arthritis With Active Flare
Primary: Part I: Percentage of Patients Who Were on Steroids at Entry Into Part I and Who Were Able to Taper Steroid as Per Protocol in at Least 25% of the Patients Who Entered…